Prasugrel: A Review of its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
- Coronary arterial sling operation. Lund, J.; Kelbaek, H. // Heart;Jul2003, Vol. 89 Issue 7, p744
Reports on the case study of a patient with severe myocardial ischemia which occurred ten days after a Q wave infarction treatment with thrombolysis. Detection of three vessel disease of the heart; Performance of coronary angiography; Use of the arterial sling operation.
- Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation. Dunn, C.J.; Foster, R.H. // PharmacoEconomics;1999, Vol. 16 Issue 6, p711
Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary revascularisation in patients with...
- The Biochemical and Physical Process of Fibrinolysis and Effects of Clot Structure and Stability on the Lysis Rate. Weisel, J. W.; Litvinov, R. I. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 3, p161
The effectiveness of fibrinolysis results from the combination of regulated enzymatic activity and the physical properties of the fibrin scaffold. Physiologically, clots or thrombi are dissolved from within via internal lysis. In contrast, with therapeutic thrombolysis, lytic agents are...
- Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. Maeda, A.; Ando, H.; Asai, T.; Ishiguro, H.; Umemoto, N.; Ohta, M.; Morishima, M.; Sumida, A.; Kobayashi, T.; Hosohata, K.; Ushijima, K.; Fujimura, A. // Clinical Pharmacology & Therapeutics;Feb2011, Vol. 89 Issue 2, p229
We examined the influence of CYP2C19 polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. The platelet aggregation induced by 20 Âµmol/l adenosine diphosphate (ADP) and CYP2C19 single-nucleotide polymorphisms (*2 and *3) was determined in patients with coronary artery...
- Stress echo after revascularization may not improve outcomes. // Pulse International;9/14/2012, Vol. 13 Issue 17, p14
The article reports that according to a study published in the journal "Archives of Internal Medicine" repeat coronary revascularization does not improve outcomes in patients with high-risk exercise echocardiography and cites that recurrent ischemia doubled mortality rate in the patients.
- Drug-eluting Stents. S. Bölükbas; J. Jähne; J. Schirren // Der Chirurg;Jun2009, Vol. 80 Issue 6, p502
ZusammenfassungÂ Â Die perkutane Koronarintervention (PCI) hat eine besondere Rolle in der Therapie der koronaren Herzerkrankung. â€žDrug-elutingâ€œ Stents (DES) bedingen eine duale Thrombozytenaggregationshemmung fÃ¼r mindestens ein Jahr. Diese Medikation erschwert planbare und...
- Hypothermia-induced platelet aggregation and cognitive decline in coronary artery bypass surgery: a pilot study. Hall, Matthew W.; Hopkins, Ramona O.; Long, James W.; Mohammad, S. Fazal; Solen, Kenneth A. // Perfusion;May2005, Vol. 20 Issue 3, p157
Hypothermia-induced platelet aggregation (HIPA) was previously reported in whole blood exposed to synthetic surfaces at 24Â° -32Â°C in one-third of normal subjects tested. Cardiopulmonary bypass, conducted with hypothermia, may lead to such aggregation, resulting in microvascular occlusion...
- Drug-Eluting Stents ï¿½ Pushing the Envelope beyond the Labels? Carrozza, Joseph P. // New England Journal of Medicine;1/24/2008, Vol. 358 Issue 4, p405
The author reflects on the controversial use of drug-eluting stents for patients with coronary heart disease. The use of drug-eluting stents became somewhat default with most of the indications being off-label until data suggested a higher rate of patients with thrombotic occlusion who used the...
- Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]. Kakafika, Anna I.; Mikhailidis, Dimitri P.; Wierzbicki, Anthony S.; Karagiannis, Asterios; Athyros, Vasilios G. // Current Vascular Pharmacology;Jul2007, Vol. 5 Issue 3, p173
Full text avialable